Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients’ lives, today announced that Aetna, Inc.’s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences’ interventional glaucoma technologies.

“We are pleased that Aetna’s rigorous clinical review resulted in expanded coverage for implant-free, minimally invasive glaucoma surgery (MIGS) procedures, including OMNI and SION. This reinforces the important role these technologies can play in the glaucoma treatment paradigm,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “With this coverage milestone, broad payer access has been established for canaloplasty and goniotomy enabled by the OMNI Surgical System and SION Surgical Instrument across all major national payers. We appreciate our surgeon customers, key opinion leaders, state and national societies, Aetna medical directors, and our market access team whose engagement helped advance medically necessary access to MIGS care for glaucoma patients.”